HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emerson Offers E-Commerce To Help Health Care Practitioners Continue Selling Supplements

This article was originally published in The Rose Sheet

Executive Summary

At least one-third of consumers who have bought supplements from health care providers currently are buying the products online, with Amazon.com the most common seller, says Adam Carr, CEO of Emerson Ecologics. One driver for the trend, in addition to consumers generally using e-commerce for more products, is that Amazon shifted to include premium supplement brands, those previously available only through doctors or other health care practitioners.

You may also be interested in...



Thorne Research Rebranding Launches With At-Home Biomarker Tests

Thorne Research rebrands, launches at-home biomarker, adds exclusive provider and technology agreements and gains Mitsui Group funding.

Supplement Firms Develop Health Care Provider Channel

The market for supplements sold by health care providers heats up, with firms offering practitioner-focused labeling, custom brands and products targeted to specific patient needs. As supplement use grows, more practitioners are interested in guiding patients’ choices in vitamins and other nutritionals.

Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation

Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel